Discussion
Enrollment has been wrapped up in a large, worldwide, late-stage clinical trial that’s testing the therapy candidate zorevunersen for reducing seizures in children and teens with Dravet syndrome. According to developer Stoke Therapeutics, which is sponsoring the Phase 3 study, October marked the completion of recruitment of…